Suggested remit: To appraise the clinical and cost effectiveness of lenvatinib with pembrolizumab within its marketing authorisation for treating previously treated advanced, metastatic or recurrent endometrial cancer.
Status In progress
Process STA 2018
ID number 3811

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
16 November 2020 - 14 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 March 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance